Table 3.
Patient characteristics according to the LMR ≥ 2.5 versus <2.5
| Characteristics | Classification | LMR ≥ 2.5 | LMR < 2.5 | p value |
|---|---|---|---|---|
| Sex | Male | 67 (58.3 %) | 44 (75.9 %) | 0.065 |
| Female | 48 (41.7 %) | 14 (24.1 %) | ||
| Age | <60 years | 69 (60.0 %) | 36 (62.1 %) | 0.711 |
| ≥60 years | 46 (40.0 %) | 22 (37.9 %) | ||
| Primary site | Stomach | 77 (67.0 %) | 24 (41.4 %) | 0.064 |
| Ileocecal | 8 (7.0 %) | 8 (13.8 %) | ||
| Small intestine | 18 (15.7 %) | 15 (25.9 %) | ||
| Colorectal | 12 (10.4 %) | 11 (18.9 %) | ||
| B symptoms | No | 78 (67.8 %) | 25 (43.1 %) | 0.005 |
| Yes | 37 (32.2 %) | 33 (56.9 %) | ||
| Lugano stage | I–II stage | 78 (67.8 %) | 32 (55.2 %) | 0.135 |
| III–IV stage | 37 (32.2 %) | 26 (44.8 %) | ||
| IPI | ≤2 score | 88 (76.5 %) | 36 (62.1 %) | 0.052 |
| >2 score | 27 (23.5 %) | 22 (37.9 %) | ||
| Immune subtype | GCB | 43 (37.4 %) | 21 (36.2 %) | 0.742 |
| nGCB | 72 (62.6 %) | 37 (63.8 %) | ||
| Hb | >11 g/dL | 83 (72.2 %) | 35 (63.8 %) | 0.199 |
| ≤11 g/dL | 32 (27.8 %) | 23 (39.7 %) | ||
| LDH | ≤240 | 81 (70.4 %) | 26 (44.8 %) | 0.003 |
| >240 | 34 (29.6 %) | 32 (55.2 %) | ||
| β2m | ≤2.6 | 78 (67.8 %) | 19 (32.8 %) | <0.001 |
| >2.6 | 37 (32.2 %) | 39 (67.2 %) | ||
| Surgery | No | 34 (29.6 %) | 24 (41.4 %) | 0.202 |
| Yes | 81 (70.4 %) | 34 (58.6 %) |
IPI international prognostic index, Hb hemoglobin, LMR lymphocyte–monocyte ratio, LDH lactate dehydrogenase, β2m β 2-microglobulin